Health innovation and development in Asia landscape

  • co11ab
  • consumer, consumerhealth, biotech
  • July 12, 2023
Health innovation and development in Asia landscape

The microbiome has gained more attention in recent years in relation to holistic health, such as gut health and skin health, which has led to the interest of consumer health companies. We felt privileged to collaborate with Haleon, a world-leading consumer health company, on a joint seminar to discuss Health Innovation and Development in the Asian Landscape.

Starting from academic research, the Lee Kong Chian School of Medicine shared the recent launch of the Centre for Microbiome Medicine, aiming to find new ways to treat obesity and chronic diseases. The various research areas include nutrition, metabolism, airways, and lungs.

It was interesting for the audience to understand the considerations Haleon has put in place to gain a deep understanding of consumers and successfully bring the product to the market, bearing in mind the regulatory differences in various countries. The journey does not stop there; even after products are launched, Haleon continues to collect feedback from consumers and improve to ensure customer satisfaction with the quality.

Kazuyuki Kasahara (Lee Kong Chian School of MedicineNanyang Technological University Singapore)
Alicia A.J. Ng (Vice-President, Head of R&D, Wider Asia, Haleon)
Karina Ong (Asia pacific Strategic Portfolio Management Head, Haleon)
Jerry Lin (Wider Asia Regulatory Innovation Lead)
Katherine Mendoza (Consumer Science & Product Experience (CSPX) Lead – APAC and China)
Bernard Ng (Group CEO, Meta Health)
Ryo Sueyoshi (Director, BD & Strategic Alliance, KINSLABO SINGAPORE PTE. LTD.)

Co-organizer: Haleon 

Latest News & Events

Subscribe To Our Newsletter

Join our mailing list to get updated with our latest news and events!

Contact Information
  • Lee Kong Chian School of
    Clinical Sciences Building
    11 Mandalay Road #16-01
    Singapore 308232

  • +65 6513 6058
Members Login

co11ab Novena (co11ab) is a Bio MedTech incubator – forged through a tripartite alliance between Nanyang Technological University, Singapore (NTU Singapore), Agency for Science, Technology, and Research (A*STAR), and National Healthcare Group (NHG) – which aims to nurture and support the translational development of biomedical technologies. Our key focus areas are biotech, medtech and digital health.